Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

University of Toronto

$141,225.00

High-throughput screening of cell contraction for applications in regenerative medicine and drug testing

FY 2013-14

Summary
We will develop and test a novel method to quantify the contractile activity of cultured cells that will be established as a high throughput screening (HTS) format for industrial applications. HTS quantification of cell contraction is a pivotal yet not available functional test with important fields of application: 1) Functional contraction tests for mesenchymal stem cells to be used to enhance tissue repair, e.g., chronic wound healing associated with diabetes (>3 Mio Canadians, ~13 Bio $) or to regenerate diseased cardiovascular tissues (>10 Mio Canadians, ~18 Bio $). 2) HTS of drugs to tune cell contractility in the cardiovascular system, in fibrosis and in cancer research. We have recently developed a novel rubber polymer that allows optical analysis of cell contraction. Essential improvements over existing deformable culture substrates can turn the new material into a widely-used assay: a) it can be provided in any cell culture format; b) it can be tuned to respond to thespecific requirements and force levels of different cell types; c) it is compatible with all standard biochemical and genetic tests; d) it has superb optical properties, and e) it has ideal storing and shipping properties. We will pursue two main objectives: 1) To upgrade our technology for ready-to-use applications, we will apply novel protocols to promote celladhesion, enable automated analysis, and tune substrates to specific cell types of industrial interest. 2) To translate the technology to a HTS format for industrial use, we will establish multi-well HTS wrinkling plates. With support from our company partners and profiting from our own expertise, we will apply our HTS system to industrially relevant fields: mesenchymal stem cell therapy, anti-fibrosis and anti-cancer drug testing. Together, contraction-associated diseases represent a hundreds of Bio $ burden for the Canadian healthcare system. Providing for the first time an HTS in vitro contraction test will result in dramatically reduced costs for Canadian health care and drug development.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
413783-2012
Name nom
Hinz, Boris
Department département
Dentistry, Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2012
Award amount
141225
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
5110
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cytoskeleton
Research subject fr
Cytosquelette
Partie
2 & 3
Nb partie
3
Application title
High-throughput screening of cell contraction for applications in regenerative medicine and drug testing
Keyword
NSERC
Application summary
We will develop and test a novel method to quantify the contractile activity of cultured cells that will be established as a high throughput screening (HTS) format for industrial applications. HTS quantification of cell contraction is a pivotal yet not available functional test with important fields of application: 1) Functional contraction tests for mesenchymal stem cells to be used to enhance tissue repair, e.g., chronic wound healing associated with diabetes (>3 Mio Canadians, ~13 Bio $) or to regenerate diseased cardiovascular tissues (>10 Mio Canadians, ~18 Bio $). 2) HTS of drugs to tune cell contractility in the cardiovascular system, in fibrosis and in cancer research. We have recently developed a novel rubber polymer that allows optical analysis of cell contraction. Essential improvements over existing deformable culture substrates can turn the new material into a widely-used assay: a) it can be provided in any cell culture format; b) it can be tuned to respond to thespecific requirements and force levels of different cell types; c) it is compatible with all standard biochemical and genetic tests; d) it has superb optical properties, and e) it has ideal storing and shipping properties. We will pursue two main objectives: 1) To upgrade our technology for ready-to-use applications, we will apply novel protocols to promote celladhesion, enable automated analysis, and tune substrates to specific cell types of industrial interest. 2) To translate the technology to a HTS format for industrial use, we will establish multi-well HTS wrinkling plates. With support from our company partners and profiting from our own expertise, we will apply our HTS system to industrially relevant fields: mesenchymal stem cell therapy, anti-fibrosis and anti-cancer drug testing. Together, contraction-associated diseases represent a hundreds of Bio $ burden for the Canadian healthcare system. Providing for the first time an HTS in vitro contraction test will result in dramatically reduced costs for Canadian health care and drug development.
University of Toronto - $141,225 Grant (2013-14) | Canada Spends